Myriad Logo
  • Patients
    • I need help with…
      • Understanding hereditary cancer riskWhat is my risk of developing hereditary cancer?
      • Treating cancerWhat are my treatment options?
      • Prenatal careIs my baby at risk for a genetic condition?
      • Managing mental healthHow might my genes affect my medication outcomes?
    • (sidebar parent)
      • About genetic testing
        • What are the costs of genetic testing?
        • Financial assistance
      • Patient Resources
        • How does genetic testing work?
        • Patient record request
      • Prostate Cancer
        • What are my treatment options?
  • Providers
    • My patient needs a test for…
      • Assessing hereditary cancer riskWhat is my patient’s risk of developing hereditary cancer?
      • Cancer treatmentWhat is the best treatment for my patient?
      • Prenatal careWhat is a pregnancy’s risk of genetic disease?
      • Mental health treatmentHow will my patient metabolize or respond to certain medications?
    • (sidebar parent)
      • About our tests
        • Myriad test catalog
        • Research & whitepapers
        • MyRisk® gene table
      • Provider resources
        • Order a test
        • Order patient materials
        • Documents & forms
        • Scope of service & lab certificates
      • Prostate Cancer Treatment
        • What are my patient’s treatment options?
  • Our Tests
    • Tests for…
      • (column wrapper)
        • Prenatal care
          • Chromosome conditions
          • Genetic diseases
        • Cancer risk assessment
          • Hereditary cancer
        • Mental health
          • Depression
          • Anxiety
          • ADHD
      • (column wrapper)
        • Cancer management
          • Breast cancer
          • Ovarian cancer
          • Pancreatic cancer
          • Prostate cancer
          • Endometrial cancer
          • Other cancers
          • All tests
    • (sidebar parent)
      • TESTS BY SPECIALTY
        • Oncology
        • Urology
        • Imaging
        • OB/GYN
        • Mental Health
        • Internal/Primary care
        • All tests
      • TESTS BY NAME
        • BRACAnalysis CDx®
        • EndoPredict®
        • Foresight®
        • GeneSight®
        • MyChoice® CDx
        • MyRisk® (cancer treatment)
        • MyRisk® (cancer risk)
        • Prequel®
        • Precise™ Tumor
        • Prolaris®
  • About Myriad
    • Who we are
      • Our science & innovation
      • Corporate & social responsibility
    • Latest news
      • Myriad Genetics Blog
    • Corporate information
      • Our leadership
      • Patient advocacy partners
      • Investor relations
      • Careers
    • Partnerships
      • Companion diagnostics
ORDER
    Order
  • Patients
    • I need help with…
      • Understanding hereditary cancer riskWhat is my risk of developing hereditary cancer?
      • Treating cancerWhat are my treatment options?
      • Prenatal careIs my baby at risk for a genetic condition?
      • Managing mental healthHow might my genes affect my medication outcomes?
    • (sidebar parent)
      • About genetic testing
        • What are the costs of genetic testing?
        • Financial assistance
      • Patient Resources
        • How does genetic testing work?
        • Patient record request
      • Prostate Cancer
        • What are my treatment options?
  • Providers
    • My patient needs a test for…
      • Assessing hereditary cancer riskWhat is my patient’s risk of developing hereditary cancer?
      • Cancer treatmentWhat is the best treatment for my patient?
      • Prenatal careWhat is a pregnancy’s risk of genetic disease?
      • Mental health treatmentHow will my patient metabolize or respond to certain medications?
    • (sidebar parent)
      • About our tests
        • Myriad test catalog
        • Research & whitepapers
        • MyRisk® gene table
      • Provider resources
        • Order a test
        • Order patient materials
        • Documents & forms
        • Scope of service & lab certificates
      • Prostate Cancer Treatment
        • What are my patient’s treatment options?
  • Our Tests
    • Tests for…
      • (column wrapper)
        • Prenatal care
          • Chromosome conditions
          • Genetic diseases
        • Cancer risk assessment
          • Hereditary cancer
        • Mental health
          • Depression
          • Anxiety
          • ADHD
      • (column wrapper)
        • Cancer management
          • Breast cancer
          • Ovarian cancer
          • Pancreatic cancer
          • Prostate cancer
          • Endometrial cancer
          • Other cancers
          • All tests
    • (sidebar parent)
      • TESTS BY SPECIALTY
        • Oncology
        • Urology
        • Imaging
        • OB/GYN
        • Mental Health
        • Internal/Primary care
        • All tests
      • TESTS BY NAME
        • BRACAnalysis CDx®
        • EndoPredict®
        • Foresight®
        • GeneSight®
        • MyChoice® CDx
        • MyRisk® (cancer treatment)
        • MyRisk® (cancer risk)
        • Prequel®
        • Precise™ Tumor
        • Prolaris®
  • About Myriad
    • Who we are
      • Our science & innovation
      • Corporate & social responsibility
    • Latest news
      • Myriad Genetics Blog
    • Corporate information
      • Our leadership
      • Patient advocacy partners
      • Investor relations
      • Careers
    • Partnerships
      • Companion diagnostics

News Releases

Mar 02, 2023
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Products
Mar 01, 2023
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
Products
Feb 28, 2023
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
Financial
Feb 22, 2023
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
Financial
Feb 09, 2023
Myriad Genetics to Participate in Upcoming Healthcare Conferences
Financial
Feb 07, 2023
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
Products
Jan 05, 2023
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
Products
Jan 04, 2023
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
Corporate
Dec 19, 2022
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
Corporate
Dec 08, 2022
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
Products
Nov 29, 2022
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
Products
Nov 17, 2022
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Products
Nov 14, 2022
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
Products
Nov 10, 2022
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
Products
Nov 03, 2022
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
Products
Next page
  • Managed care
    • Payers
  • Investors
    • Investor relations
  • News
    • Press releases
    • Myriad Genetics’ Blog
  • About
    • Careers
    • Contact us
  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • HIPAA Notice of Privacy Practices
  • Language Assistance
  • Cookie Preferences
facebook linkedin twitter instagram youtube

Health. Illuminated.

  • © 2023 Myriad Genetics, Inc.